Bioretec

Bioretec sees opportunities to expand its product portfolio into spinal applications, with preclinical studies already underway.

We expect revenue to grow as the commercialization of the RemeOs product family progresses in the US and Europe.

We expect the company to show clear signs of growth this year.

The cost structure is being adjusted to reflect actual demand.

The company is seeking additional savings of 0.2 MEUR, as production capacity is still too high relative to demand.

7:09

Bioretec's Q1 earnings positively surprised in terms of revenue and profit, particularly due to growth in the US and European markets.

Bioretec's start to the year offered a positive surprise.